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Abstract
Background: The intermediate filament proteins keratins 18 (K18) and 8 (K8) polymerize to form the cytoskeletal
network in the mature hepatocytes. It has been shown that the phosphorylation of K18 at two serine residues, 33
and 52, correlates with the progression of hepatitis C, but little is known of chronic hepatitis B (CHB). In this study,
we examined K18 phosphorylation in relation to CHB.
Results: Site-specific phosphorylation of K18 was determined in livers of twelve healthy donors, and non-cirrhosis
(n = 40) and cirrhosis (n = 21) patients. On average, progressively higher level of Ser52 phosphorylation was
observed in non-cirrhotic and cirrhotic livers, while elevated Ser33 phosphorylation was detected in both livers but
no significant difference. Progressive increase of Ser33 and Ser52 phosphorylation correlated with the elevation of
both histological lesions and enzymatic activities of alanine aminotransferase in non-cirrhotic livers. In the
hepatocytes of an inactive HBV carrier, strong signals of Ser33 phosphorylation were co-localized with viral
infection, while only basal level of Ser52 phosphorylation was detected in infected cells.
Conclusion: Assuming all obtained data, our data suggest that K18 phosphorylation is a progression marker for
CHB.
Background
Keratin 18 (K18) is a member of the intermediate fila-
ment family comprising ~70 cytoskeleton proteins.
Adult hepatocytes contain only K18 and keratin 8 (K8),
heteropolymerized to form the filament networks that
protect the cells from various mechanical stresses [1-3].
Serious hepatocellular injures usually result in damages
in the filament scaffolds. For example, during apoptosis
K18 is cleaved into small fragments by caspases. As a
suitable indicative of hepatocytic apoptosis in vivo, one
of the K18 proteolytic fragments, termed tissue polypep-
tide-specific antigens (TPS), can be readily detected in
the plasmas of patients suffering from alcoholic hepatitis
[4], nonalcoholic steatohepatitis[5,6], chronic cholecysti-
tis [7] and chronic hepatitis B (CHB) [8]. In addition to
scaffolding function, keratin filaments form complex sig-
naling platforms and interact with kinases, adaptors and
apoptotic proteins. K18 is involved in modulating
hepatocytic apoptosis induced by Fas/TNF family recep-
tors [9-11]. It has been shown that it attenuates TNF-
induced cytotoxicity by sequestering the TNF receptor
type 1-associated death domain (TRADD) protein from
its interaction with the TNF receptor-1 (TNFR1) [12].
K18 is also important for other cellular processes such
as mitosis [13], cell cycle progression [14] and responses
to stresses [15].
K18 is modified post-translationally at multiple amino
acid residues. Many of these modifications are implicated
in the functions other than scaffolding. It has been
shown that phosphorylation of K18 is most important for
its functions in several processes and likely plays a role in
liver diseases. For example, the K18 phosphorylation at
Ser33 regulates keratin filament organization and modu-
lates its binding to 14-3-3 protein, which in turn, regu-
lates nuclear 14-3-3 redistribution during mitosis and
may play a role in hepatocyte mitotic progression [13,16].
On the other hand, the phosphorylation at Ser52 could
be involved in protecting hepatocytes from toxin- and
stress-induced liver injuries [15]. Furthermore, hyperpho-
sphorylation of K18 is associated with the human liver
diseases. Site-specific K18 hyperphosphorylation was
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shown to strongly correlate with the progression of liver
diseases in patients with chronic noncirrhotic hepatitis C
virus (HCV) [17]. Mallory-Denk bodies (MDBs), hepatic
inclusion bodies observed in diverse chronic liver diseases
such as alcoholic and non-alcoholic steatohepatitis,
chronic cholestasis, metabolic disorders and hepatocellu-
lar neoplasms, are composed of aggregates of, in addition
to other proteins, K18 and K8 in disproportional ratio
that are hyperphosphorylated at multiple residues in both
keratins, including Ser33 and Ser52 in the former, and
Ser73 and Ser 341 in the latter [18-22].
The pathogenesis of viral hepatitis is complex and has
been attributed to many factors. Possible mechanisms of
chronicity in HCV include failure of the immune
responses to viral infection that results in inappropriate
or ineffective induction of cytotoxic T lymphocytes
(CTLs) and production of cytokines. They may lead to
continued viral replication, non-specific inflammatory
response and fibrosis [23]. Dysregulation of proliferative
and apoptotic pathways represents a pro-tumorigenic
principle in human hepatocarcinogenesis. Down-regula-
tion of FAS/FAS-L has been detected in patients with
chronic hepatitis caused by HCV, suggesting a role of
FAS-mediated hepatocytic apoptosis in eliminating
infected cells [24]. In the case of primary hepatocellular
carcinoma (HCC), integration of the X gene (HBx) of
hepatitis B virus (HBV) into the host genome and the
ability of the mutant HBx protein to bind to p53 and
abrogate p53-mediated apoptosis are implicated in the
etiology and molecular pathogenesis [25,26].
The involvement of hepatocytic keratins in apoptosis
and other signal pathways prompted us to examine the
potential role of K18 phosphorylation in the progression
of HBV chronic hepatitis and/or the severity of liver his-
tological lesions. In this report, we evaluated the phos-
phorylation of K18 in liver tissues chronically infected
with HBV, and determined their enzymatic activities of
aspartate (AST) and alanine (ALT) aminotransferases,
and histological lesions. Our results indicate that K18
phosphorylation at Ser33 and Ser52 may serve as reli-
able markers for progression of chronic hepatitis B.
Results
K18 phosphorylation is a marker of progression of
chronichepatitis B
HBV infection leads to various clinical presentations,
ranging from an inactive carrier state to self-limited
acute or chronic hepatitis with progression to cirrhosis
and HCC. In this study, we examined the K18 phos-
phorylation in normal livers and those with chronic
non-cirrhotic hepatitis and cirrhosis (Fig. 1A). Liver
homogenates containing equal amount of proteins were
Figure 1 K18 Phosphorylation in normal, chronic non-cirrhotic
hepatitis and cirrhosis livers. (A) Representative immunoblots of
tubulin, K18, Ser33 and Ser52 phosphorylated K18 (K18 pSer33 and
K18 pSer52, respectively) from livers of indicated sources. (B) Relative
levels of Ser33 phosphorylated K18 from livers of healthy donors
(squares), and patients with chronic non-cirrhotic hepatitis (circles)
and cirrhosis (triangles). The intensity of K18 of each sample was
used to normalize that of K18 pSer33, with the average of each
group is shown in the box. The P-values of pair-wise comparisons
are indicated on the top. (C) Relative levels of Ser52 phosphorylated
K18 from livers of indicated sources, with symbols as the same in B.
The P-values are indicated on the top.
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analyzed by immunoblots probed with antibodies against
phosphorylated serine at specific serine residues in K18,
and the relative levels of phosphorylation were quanti-
fied. While the levels of Ser52 phosphorylation in the
normal livers (n = 12) were relatively low with minor
fluctuations, those in the chronic non-cirrhotic hepatitis
(n = 40) varied in a greater range with an average that
was significantly higher than the normal controls (P <
0.001) (Fig. 1B). In cirrhotic livers (n = 21), increased
levels of Ser52 phosphorylation were detected, with the
average significantly higher than the normal (P < 0.001)
and the chronic non-cirrhotic hepatitis livers (P < 0.001)
(Fig. 1B). The range of Ser33 phosphorylation in the
normal livers was similar to those of Ser52 (Fig. 1C).
Significant increases were observed in both chronic
non-cirrhotic hepatitis (P < 0.001) and cirrhotic (P <
0.001) specimens. However, there was no significant dif-
ference in the levels of Ser33 phosphorylation between
the latter two groups (P = 0.954) (Fig. 1C). These results
suggest that on average Ser52 phosphorylation increases
with the progression of hepatitis B, and that Ser33 phos-
phorylation increases in hepatitis B, but remains largely
unchanged with the progression of the disease.
However, much deviation and overlapping of K18
phosphorylation was observed in the two groups of the
diseased livers (Figs. 1B and 1C). We then asked the
question whether there was any correlation between
K18 phosphorylation and subgroups or progression of
liver lesions within the same group. The 21 cirrhotic
specimens were classified to two groups, active (active
LC, n = 11) and inactive (inactive LC, n = 10) liver cir-
rhosis (Fig. 2A)[27]. We divided the 41 chronic non-cir-
rhotic hepatitis livers to three groups according to
Ishak’s staging classification [28]: minimal histological
lesions (MiH, n = 13), with grading score < 4 and/or
staging score < 2; medium lesions (MeH, n = 17), with
4 ≤ grading scores < 8 and 2 ≤ staging score < 3; and
advanced lesions (AdH, n = 10), with two scores greater
than 8 and 3, respectively (Fig. 2B). The same set of
normal livers (n = 12) was included as controls.
The mean relative levels of Ser33 phosphorylation
were 1.015, 1.710, 2.500, 3.430, 1.790 and 3.330 for nor-
mal, MiH, MeH, AdH, inactive LC and active LC sub-
groups, respectively (Fig. 2D). Significant differences
(P < 0.005) were observed in any pair of these six sub-
groups, with the exceptions of MiH vs. inactive-LC
(P = 0.750) and AdH vs. active-LC (P = 0.715). Similarly,
the mean relative levels of Ser52 phosphorylation in the
six groups mentioned above were determined to be
0.730, 1.078, 1.556, 2.712, 3.003, and 3.644, respectively
(Fig. 2C). Significant differences (P < 0.05) were noted
in any pair, with the exception of normal vs. MiH
(P = 0.168) and AdH vs. inactive-LC (P = 0.289).
These results indicate an overall increase in K18
phosphorylation at both Ser33 and Ser52 with the pro-
gression of CHB. There are however minor differences
between these phosphorylation events, as the relative
level of Ser33 phosphorylation follows the trend of nor-
mal < MiH ≈ inactive LC < MeH < AdH ≈ active LC,
and that of Ser52 normal < MiH < MeH < AdH < inac-
tive LC < active LC.
K18 Ser52 phosphorylation is a marker of liver injury, and
Ser33 phosphorylation is related to HBV infection
Many biochemical and serological markers have been
used to evaluate liver injuries. Among these, liver func-
tions (e.g., ALT and AST) are most commonly used.
We tested 40 CHB livers for their ALT activities and
divided them to 3 subgroups: A, ALT < 40 U/L (n =
12); B, 40 ≤ ALT < 200 U/L (n = 18); and C, ALT =
200 U/L (n = 10). We then compared K18 phosphoryla-
tion in these three groups and the 12 normal livers (Fig.
3A). Ser52 phosphorylation was equivalent in the con-
trol and subgroup A (P = 0.976), while significant
increase was noted between subgroups A and B (P <
0.001), and subgroups B and C (P < 0.001) (Fig. 3B).
The positive correlation between levels of phosphoryla-
tion and ALT activities suggests that the phosphoryla-
tion of Ser52 in K18 is progressively related to liver
injuries. On the other hand, significant increase in Ser33
phosphorylation was detected in group A compared
with the control (P < 0.05). This increase could be an
indicative of HBV infection, in addition to a marker of
liver injuries. Incremental increases in Ser33 phosphory-
lation were also observed between subgroups A and B
(P < 0.05), and B and C (P = 0.104), respectively.
Since direct comparisons between Ser33 phosphoryla-
tion in K18 and HBV infection at a cytomorphological
level have not been reported frequently, we sought to
determine if there was any correlation. A liver specimen
respectively from a randomly selected inactive HBV car-
rier and a healthy donor was sectioned, and probed for
HBsAg and phosphorylated Ser33 or Ser52. In the sec-
tion of HBV-infected patient maintaining normal liver
functions, strong signals of phosphorylated Ser33 were
restricted to hepatocytes with strong positive detection
of HBsAg (Figs. 4A and 4A’). However, only basal levels
of Ser33 phosphorylation were detected in the control
(Figs. 4C and 4C’), while basal levels of Ser52 phosphor-
ylation were observed in both HBV positive (Figs. 4B
and 4B’) and healthy (Figs. 4D and 4D’) samples. These
results reiterate the conclusion that phosphorylation at
Ser33 in K18 is reflective of HBV infection.
Discussion
Posttranslational modifications, e.g., phosphorylation,
glycosylation, acetylation, methylation and ubiquitina-
tion, play important roles in functional modulation of
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the intermediate filament proteins. In particular, site-
specific phosphorylation of keratins 8 and 18 is involved
in regulating the keratin filament structure, interactions
with other proteins and other cellular processes [16,29].
Abnormality and hyperphosphorylation of keratins is
associated with a variety of liver injuries and diseases.
For example, large aggregates of misfolded hyperpho-
sphorylated K8/K18, in disproportional ratio, were
found in MDBs of alcoholic hepatitis in both humans
and mice [18]. The correlation between keratin phos-
phorylation and hepatitis C led to the suggestion that
the former is a progression marker of the latter when
increased [17]. It is therefore crucial to investigate
whether there is similar correlation between K18 phos-
phorylation and CHB caused by viral infection, as it is
the most predominant cause of liver disease in China.
We examined liver specimens of 61 patients (40 with
chronic non-cirrhotic hepatitis, 21 with cirrhosis) and 12
normal controls. We found that on average Ser52
phosphorylation increased with the progression of CHB,
and reached the highest level in cirrhotic livers (Fig. 1C),
indicating that it is a progression marker of CHB, as in
the case of hepatitis C. Higher levels of Ser33 phosphory-
lation were also observed in both chronic non-cirrhotic
hepatitis and cirrhosis compared with the controls. How-
ever, the difference between the two was statistically neg-
ligible (Fig. 1B). An earlier study indicated that Ser33
phosphorylation was higher in HCV non-cirrhotic livers
than in those of cirrhosis [17]. This discrepancy is likely
due to the difference between HBV and HCV hepatitis
(see below). These results prompted us to examine the
level of K18 phosphorylation in chronic non-cirrhotic
livers at different stages as determined by characteristic
histological changes, and active and inactive cirrhotic
livers (Fig. 2). Although overlapping was observed, Ser52
phosphorylation in general increased progressively with
inflammation level, and the average level was higher in
active than non-active cirrhosis (Fig. 2D). It is thus
Figure 2 K18 phosphorylation in relation to histological progression of CHB. (A) Representative immunoblots of indicated proteins from a
control (lane C), inactive (lanes 1-4) and active (lanes 5-8) cirrhotic livers. (B) Representative immunoblots of indicated proteins from livers with
progressive histological lesions, MiH (lanes 1-3), MeH (lanes 4-6) and AdH (lanes 7-9), minimal, medium and advanced histological lesions,
respectively. (C) The box and whisker plot of the relative levels of Ser33 phosphorylation of K18 in livers of the normal donors, and patients with
CHB at different progression stages. Three outliers are indicated by open dots. Significant difference (P < 0.005) was observed in any pair with
the exception of MiH vs. inactive LC (liver cirrhosis, P = 0.750), and AdH vs. active LC (P = 0.715), respectively. (D) The box whisker plot of relative
levels of Ser52 phosphorylation of K18 in livers from indicated sources. The four outliers are indicated by open dots. Significant difference
(P < 0.05) was observed in any pair with the exception of normal vs. MiH (P = 0.168), and AdH vs. inactive LC (P = 0.289), respectively.
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evident that Ser52 phosphorylation reflects largely the
chronic progression of liver diseases. Ser33 phosphoryla-
tion in the inactive cirrhotic livers, on the other hand,
was significantly lower than in the active ones. It was also
lower than that in the non-cirrhotic livers with higher
levels of inflammation (i.e.; MeH and AdH histological
subgroups) (Fig. 2C). The level of phosphorylation at
Ser33 in K18 seems to correlate with the extent of
inflammation. Our results are in consistent with the
known implication of Ser33 phosphorylation in resistance
to the Fas-mediated apoptosis [10] and sequestering the
TRADD protein involved in induction of apoptosis [12],
and protective function of Ser52 phosphorylation against
hepatotoxic injuries [15].
These conclusions are in agreement with our analyses
of the relative level of K18 phosphorylation in livers clas-
sified according to ALT activities (Fig. 3). While phos-
phorylation of Ser52 increased in livers with elevated
ALT (≥ 40 U/L) (Fig. 3C), phosphorylation of Ser33 was
observed in HBV infected livers regardless of ALT activ-
ities (Fig. 3B). To our knowledge, this is the first time
that K18 phosphorylation was directly compared with
ALT activities in diseased livers. The association of Ser33
phosphorylation with HBV infection was further demon-
strated in the immunohistological analyses of the liver
sections of an inactive HBV carrier (Fig. 4). A high level
of Ser33 phosphorylation was detected in only hepato-
cytes infected with HBV, as indicated by the strong
HBsAg staining (Fig. 4A and 4A’ cf. Fig. 4B and 4B’). On
the other hand, we observed merely basal level of Ser52
phosphorylation in the hepatocytes of the carriers regard-
less of HBsAg staining (Fig. 4C and 4C’ cf. Fig. 4D and
4D’). Toivola and colleagues observed increased phos-
phorylation of both Ser33 and Ser52 in livers from
patients with chronic non-cirrhotic HCV and cirrhosis
[16]. The different cytochemistry and molecular events
induced by HBV and HCV could attribute to the differ-
ence in Ser52 phosphorylation. Nevertheless, the same
authors also observed limited reorganization of the kera-
tin filament networks in pre-cirrhotic HCV livers [17].
The absence of keratin and the destruction of cytoskele-
tal networks are the hallmarks of hepatocytic injuries
[30]. If limited reorganization of the keratin filament net-
works is also an indication of limited injuries in HCV
livers, the basal level phosphorylation of Ser52 in non-
cirrhotic HBV livers with relative low ALT activities (≤
40 U/L) may indicate that in these hepatocytes viral
infection does not cause injuries that trigger Ser52 phos-
phorylation and related cellular protection. If this is
indeed true, phosphorylation of Ser33 in K18 could serve
as an early indication of HBV infection.
In summary, phosphorylation of Ser33 and Ser52 in
K18 may serve as reliable progression markers of chronic
hepatitis B. Although it remains to be determined the
precise molecular mechanism through which HBV alters
K18 phosphorylation, specifically how differential phos-
phorylation of Ser33 and Ser52 is modulated in hepato-
cytes at different stages of the liver disease, our study
suggests that the two phosphorylation events may under-
lie different hepatocytic events associated with HBV.
Figure 3 The phosphorylation of Ser33 and Ser52 in K18 in
relation to HBV infection. (A) Representative immunoblots of
indicated proteins from livers of a healthy donor (C), and patients
(lanes 1-8) with HBV, and with enzymatic activities of aspartate (AST)
and alanine (ALT) aminotransferases (U/L) listed under the each
sample. (B, C) Relative levels of K18 phosphorylation at Ser33 (B) and
Ser52 (C) in livers of healthy individuals (normal) and HBV patients
with ALT (U/L) at low (< 40), medium (40-200) and high (> 200)
levels.
Shi et al. Virology Journal 2010, 7:70
http://www.virologyj.com/content/7/1/70
Page 5 of 8
Conclusion
In conclusion, K18 phosphorylation is a progression
marker for CHB. K18 Ser52 phosphorylation is asso-
ciated with the cellular protection in hepatocytes with
HBV infection, while phosphorylation of Ser33 in K18
may serve as an early indication of HBV infection.
Methods
Antibodies
The anit-K18 monoclonal antibody and the phospho-
specific anti-K18 Ser33 and -Ser52 polyclonal antibodies
were from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-HBsAg monoclonal antibody and anti-tubulin
monolonal antibody were from Sigma-Aldrich Co
(Eugene, OR).
Patients
Hepatitis B e-antigen (HBeAg)-negative chronic HBV
infection was diagnosed based on positive hepatitis B
surface antigen (HBsAg) and negative HBeAg for ≥ 6
months. Patients with HBeAg-negative chronic HBV
infection, persistently normal ALT activity for ≥ 12
months (determined at least every 3 months during the
first year and at least every 6 months thereafter) and
baseline serum HBV DNA below 20,000 IU/ml were
considered as inactive chronic carriers. ALT and AST
were detected by the Hitachi 7600 Series automatic bio-
chemical analyzer (Hitachi, Tokyo, Japan).
A total of 61 HBsAg positive patients were recruited
from October, 2006 to September, 2008 at You’an Hos-
pital, Capital Medical University (Beijing, China). They
were divided into two groups, 40 patients with CHB and
21 with liver cirrhosis (LC, active or inactive [27]). Nor-
mal control liver tissues were from donors undergone
liver transplantation. Those with CHB were obtained by
liver centesis. Cirrhosis specimens were obtained from
transplant programs. This study was approved by the
local ethics committee, and informed consent was
obtained from each patient.
Histological analysis
Sections of liver biopsy specimens were stained with
hematoxylin-eosin, and assessed by a pathologist with-
out prior knowledge of the clinical and virological
results. The histological changes were classified accord-
ing to Ishak et al [28].
Immunoblot analysis
Liver biopsies or explants were snap-frozen in liquid
nitrogen and kept at -80°C until use. The explant pieces
Figure 4 Detection of K18 phosphorylation and HBsAg in livers from an inactive HBV carrier (HBV+) and a healthy donor (Control).
Sections of livers were probed for HBsAg (red, A, B, C and D) and K18 phosphorylation (green, A’, B’, C’ and D’) at Ser33 (K18 pS33) or Ser52
(K18 pS52), with nuclei stained with DAPI (blue). Representative images from same visual fields (A and A’, B and B’, C and C’, D and D’) were
selected, with scale bar = 100 μM.
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or liver centesis tissues, of approximately 0.5 cm3, were
homogenized in 500 μl and 30 μl, respectively, of high
salt lysis buffer (150 mM NaCl, 1% NP-40, 0.5% deoxy-
cholate, 0.1% SDS, 50 mM Tris [pH 8.0], 5 mM EDTA)
with protease inhibitors (10 μg/ml PMSF). Total cellular
lysates were separated on 12% SDS-PAGE, and then
transferred to PVDF membrane. Following the standard
protocol, the protein blots was blocked with 5% nonfat
milk, probed sequentially with specific primary antibo-
dies and horseradish peroxidase-conjugated secondary
antibodies. The detection of specific proteins on blots
was achieved with enhanced chemiluminescence (Pierce
SuperSignal, Thermo Fisher Scientific Inc. Rockford, IL)
captured on X-ray films. The relevant bands were quan-
tified with a Bio-Rad scanning densitometer (GS-710)
using Quantity One software (Bio-Rad Laboratories Inc,
version 4.62, Hercules, CA). K18 signal was used to nor-
malize the relative level of phosphorylation of Ser33 and
Ser52.
Immunofluorescence microscopy
Frozen sections of fresh liver tissues were prepared
using the standard techniques. They were fixed with
10% formaldehyde/PBS, incubated in 1% Triton X-100/
PBS for 10 min, blocked with 3% BSA/PBS, and
probed with mouse anti-HBsAg mAb, for which tetra-
methyl rhodamine isothiocyanate (TRITC)-conjugated
secondary antibodies were used. Slices were then
probed with anti-K18 Ser52 or -Ser33 antibodies, for
which fluorescent isothiocyanate (FITC)-conjugated
second secondary antibodies were used. Nuclei were
counterstained with 4,6-diamidino-2-phenylindole
(DAPI). Sections were examined with a fluorescence
microscope (Nikon Eclipse 80i). Figures were generated
with Adobe Photoshop (Adobe Systems Inc, version
7.0, San Jose, CA).
Statistical analysis
Statistical analyses of the results were performed by Stu-
dent Newman Keuls Test (SNK) and Least Significant
Difference Procedure (LSD) with an analysis software,
Statistical Package for Social Science (SPSS Inc. version
11.5, Chicago, IL), and P < 0.05 was considered statisti-
cally significant.
Abbreviations used in this paper
(HBV): Hepatitis B virus; (CHB): Chronic hepatitis B; (K18): Keratin 18.
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